Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Psicol. (Univ. Brasília, Online) ; 37: e372515, 2021. tab, graf
Artículo en Portugués | LILACS-Express | LILACS, Index Psicología - Revistas | ID: biblio-1340376

RESUMEN

Resumo Estudo de abordagem descritiva, exploratória e retrospectiva que analisou prontuários de pacientes em tratamento pelo uso problemático de crack. Foram levantadas as prescrições, as interações medicamentosas e o perfil sociodemográfico destes pacientes. Foram feitas revisões de literaturas narrativas para verificar quais medicamentos apresentam maiores potenciais terapêuticos e para caracterizar o perfil dos usuários; dados dos prontuários e da literatura foram triangulados. Os resultados sugerem que os medicamentos utilizados no tratamento do uso problemático de crack são limitados, os medicamentos utilizados na prática não possuem evidências de eficácia, há interações relevantes nas prescrições e o perfil sociodemográfico desses usuários é semelhante com a literatura. Estudos adicionais são desejáveis para buscar um tratamento medicamentoso eficaz para o uso problemático de crack.


Abstract A descriptive, exploratory and retrospective study that analyzed medical records of the patients under treatment for crack use; prescriptions and medicines interactions were collected, and the sociodemographic profile of these patients. Revisions of narrative literatures were conducted to verify which medicines have the greatest therapeutic potentials and to characterize the profile of the crack users; data from the medical records and the literature were triangulated. The results suggest: medicines prescribed in the treatment of the crack use are limited, medicines used in practice don't have evidence of efficacy, there are relevant interactions in the prescriptions, and the sociodemographic profile of these users is similar with the literature. Additional studies are desirable to seek effective medicine treatment for crack use.

2.
Pharmacol Biochem Behav ; 196: 172982, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32645315

RESUMEN

BACKGROUND: Cannabinoids may have an important therapeutic potential for the treatment of dependence on crack cocaine. Cannabidiol (CBD), in particular, has anxiolytic, antipsychotic and anticonvulsant properties and plays a role in regulating motivation circuitry and controlling sleep disorders. Several studies were performed evaluating CBD in experimental models for cocaine. This systematic review aims evaluate the potential use of CBD in the treatment of cocaine use disorder. METHOD: Five databases (Scielo; Medline/PubMed; PsycINFO; Cochrane Library; Virtual Health Library-VHL) were searched up to January 2020. Full-text reports published in English were included if they were experimental studies that administered CBD to human and/or adult animals in use or with a history of crack/cocaine administration. The risk of bias of each study selected was appraised by two independent reviewers following the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) protocol. MAJOR FINDINGS: Fifty-one studies were analyzed, and 14 were selected. No studies conducted with humans were found; only one clinical trial was ongoing. The results were grouped into the following categories: cocaine self-administration, brain-stimulation reward, conditioned place preference, neuronal proliferation, anxiety, hepatic protection, anticonvulsant effect and locomotor sensitization response Only four studies had a low risk of bias. CBD promotes reduction on cocaine self-administration. Also, it interferes in cocaine induce brain reward stimulation and dopamine release. CBD promotes alteration in contextual memory associated with cocaine and in the neuroadaptations, hepatotoxicity and seizures induced by cocaine. CONCLUSION: The evidence indicates that CBD is a promising adjunct therapy for the treatment of cocaine dependence due to its effect on: cocaine reward effects, cocaine consumption, behavioral responses, anxiety, neuronal proliferation, hepatic protection and safety. Moreover, clinical trials are strongly required to determine whether the findings in animal models occur in humans diagnosed for cocaine or crack cocaine use disorder.


Asunto(s)
Cannabidiol/uso terapéutico , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Animales , Ansiedad/tratamiento farmacológico , Cannabidiol/farmacología , Proliferación Celular/efectos de los fármacos , Humanos , Memoria/efectos de los fármacos , Neuronas/citología , Neuronas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA